Medical technology company Becton, Dickinson and Company (BD) announced that it non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial applications.
“BD’s patented stochastic labelling technology incorporating molecular indexes (known also as UMIs or molecular barcodes), enables the precise counting of individual biological molecules, including DNA or RNA, in complex and often volume-limited samples,” said BD in a statement.
“BD is developing a suite of products utilizing this technology for accurate quantitative measurements of mRNA targets from single cells, enabling researchers to gain greater insights into the biology of complex and heterogeneous samples.”
BD said it was also working with other partners to license this technology.
“Stochastic labelling with molecular indexes is a simple, yet powerful, approach for the accurate quantification of target molecules in complex biological samples,” said Stephen Gunstream, vice president of Genomics at BD.
“This technology enables a range of future products that will broadly benefit many areas of research and future clinical applications.”
Specific financial terms of the agreement were not disclosed.